Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells

Journal of Autoimmunity

Volumn 2, Issue 5, 1989, Pages 627-642

  Herzog, Christian ^a   Walker, Christoph ^b   Müller, Wolfgang ^a   Rieber, Peter ^c   Reiter, Christian ^c   Riethmüller, Gerd ^c   Wassmer, Peter ^a   Stockinger, Hannes ^d   Madic, Otto ^d   Pichler, Werner J ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, ANTI IDIOTYPIC; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; BIOSYNTHESIS; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; EVALUATION STUDIES; HUMAN; IMMUNITY, CELLULAR; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; SUPPORT, NON-U.S. GOV'T;

EID: 0024746393     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/S0896-8411(89)80002-2     Document Type: Article

References (53)

1. Rheumatoid arthritis: Evolving concepts of pathogenesis and treatment
2. Cellular immune events in the joints of patients with rheumatoid arthritis
3. Pathogenesis of rheumatoid arthritis
4. T lymphocytes in blood and synovial fluid in rheumatoid arthritis
5. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis
6. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies
7. T cell regulatory disturbances in the rheumatic diseases
8. T cytotoxic and helper cells are markedly increased, and T suppressor and inducer cells are markedly decreased, in rheumatoid synovial fluids
9. Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis
10. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation
11. Use of monoclonal antibodies to T cell subsets for immunologic monitoring and treatment in recipients of renal allografts
12. Immunologic follow-up of renal allograft recipients treated prophylactically by OKT3 alone
13. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody
14. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
15. Tumor therapy with monoclonal antibodies
16. Monoclonal antibody: intravenous therapy in lymphoproliferative disorders
17. Immunologic effects in progressive MS patients treated with anti-T11 and anti-T4 monoclonal antibodies
18. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody anti-T12
19. In vivo effects of antibodies to immune response gene products: Prevention of experimental allergic encephalitis
20. Treatment of (NZB/NZW) F1 disease with anti I-A monoclonal antibodies
21. Treatment of murine lupus with monoclonal anti T-cell antibody
22. Successful treatment of autoimmunity in (NZB/NZW) F1 mice with monoclonal antibody to L3T4
23. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker
24. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
25. The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4
26. Induction of tolerance by monoclonal antibody therapy
27. Induction of immune tolerance by administration of monoclonal antibody to L3T4
28. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+cells
29. 1958 revision of diagnostic criteria for rheumatoid arthritis
30. Therapeutic criteria in rheumatoid arthritis
31. Empfehlungen für die Herstellung und Prüfung in vivo applizierbarer monoklonaler Antikörper
32. Epitopes of the CD4 Antigen and HIV infection
33. Preliminary criteria for clinical remission in rheumatoid arthritis
34. Circadian rhythms in circulating T lymphocytes subtypes and plasma testosterone, total and free cortisol in five healthy men
35. Effect of divided daily dose prednisone therapy on circulating T-cell subsets
36. Anti-CD4 Antibody Treatment of Patients with Rheumatoid Arthritis: II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells
37. The differentiation and function of human T cells
38. T-cell subsets and the recognition of MHC class
39. Activation of human T lymphocyte subsets: helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens
40. Clonal analysis of human cytotoxic T lymphocyte T4+effector T cells recognize products of different major histocompatibility complex regions
41. Perturbation of the T4 molecule transmits a negative signal to T cells
42. Role of the L3T4-antigen in T cell activation. II. Inhibition of T-cell activation by monoclonal anti-L3T4 antibodies in the absence of accessory cells
43. The role of L3T4 in T-cell activation: L3T4 may be both an Ia-binding protein and a receptor that transduce a negative signal
44. Lymphapheresis in rheumatoid arthritis a randomized trial
45. Anti CD4 and anti CD2 monoclonal antibody infusions in subjects with multiple sclerosis
46. Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis
47. The isolation and characterization of the human helper inducer T-cell subset
48. The isolation and characterization of the human suppressor inducer T-cell subset
49. Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen
50. The interaction of murine IgG subclass proteins with human monocyte Fc receptors
51. Administration of F(ab′)2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4 cells
52. Idiotype switching of CD4-specific monoclonal antibodies can prolong the therapeutic effectiveness in spite of host anti mouse IgG antibodies